Efficacy of ipilimumab 3mg/kg following progression on low dose ipilimumab in metastatic melanoma.

被引：0
|
作者：
Lai-Kwon, Julia Elizabeth
Jacques, Sarah
Carlino, Matteo S.
Benannoune, Naima
Robert, Caroline
Allayous, Clara
Baroudjian, Barouyr
Lebbe, Celeste
Zimmer, Lisa
Eroglu, Zeynep
Topcu, Turkan Ozturk
Dimitriou, Florentia
Haydon, Andrew Mark
Lo, Serigne N.
Menzies, Alexander M.
Long, Georgina V.
机构：
[1] Melanoma Inst Australia, Wollstonecraft, Australia
[2] Crown Princess Mary Canc Ctr, Sydney, NSW, Australia
[3] Blacktown Hosp, Blacktown, Australia
[4] Gustave Roussy, Canc Campus, Villejuif, France
[5] Gustave Roussy, Villejuif, France
[6] Paris Saclay Univ, Paris, France
[7] Hop St Louis, AP HP, Dermatol Dept, Paris, France
[8] St Louis Hosp, AP HP, Dept Dermatol, Paris, France
[9] Univ Paris, Hop St Louis, AP HP, Paris, France
[10] Univ Hosp Essen, Dept Dermatol, Essen, Germany
[11] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[12] H Lee Moffitt Canc Ctr & Res Inst, Dept Cutaneous Oncol, Tampa, FL USA
[13] Univ Zurich Hosp, Zurich, Switzerland
[14] Alfred Hosp, Melbourne, Vic, Australia
[15] Univ Sydney, Melanoma Inst Australia, Sydney, NSW, Australia
[16] Royal North Shore & Mater Hosp, Sydney, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21533
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Sequential administration of high-dose interleukin-2 and ipilimumab in patients with metastatic melanoma.
    Patel, Sapna Pradyuman
    Milton, Denai
    Milhem, Mohammed M.
    Flaherty, Lawrence E.
    Hallmeyer, Sigrun
    Feun, Lynn G.
    Hauke, Ralph J.
    Cranmer, Lee D.
    Daniels, Gregory A.
    Doolittle, Gary C.
    Taback, Bret
    Morse, Michael
    Lutzky, Jose
    Sharfman, William Howard
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [22] Dose-dependent toxicity of ipilimumab in metastatic melanoma
    Olischewsky, Alexandra
    De Schrijver, Sofie
    Bankfalvi, Agnes
    Wetter, Axel
    Zimmer, Lisa
    Livingstone, Elisabeth
    Schadendorf, Dirk
    Ugurel, Selma
    EUROPEAN JOURNAL OF CANCER, 2018, 95 : 104 - 108
  • [23] Use of ipilimumab in patients with metastatic melanoma. Experience at the Medica Sur Hospital
    Manuel Ruiz-Morales, Jose
    Rafael Rodriguez-Cid, Jeronimo
    Alvarado-Luna, Gabriela
    Green-Renner, Dan
    Motola-Kuba, Daniel
    GACETA MEXICANA DE ONCOLOGIA, 2014, 13 (03): : 157 - 161
  • [24] Ipilimumab efficacy and safety profile in metastatic melanoma in Saskatchewan
    Papneja, N.
    Olson, C.
    Lee, C. H.
    Lim, H.
    Bryce, R.
    Gesy, K.
    Iqbal, N.
    Abbas, T.
    ANNALS OF ONCOLOGY, 2016, 27
  • [25] Radiotherapy to Control Limited Melanoma Progression Following Ipilimumab
    Kropp, Lauren M.
    De Los Santos, Jennifer F.
    McKee, Svetlana B.
    Conry, Robert M.
    JOURNAL OF IMMUNOTHERAPY, 2016, 39 (09) : 373 - 378
  • [26] Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results
    Sharma, Padmanee
    Siefker-Radtke, Arlene
    de Braud, Filippo
    Basso, Umberto
    Calvo, Emiliano
    Bono, Petri
    Morse, Michael A.
    Ascierto, Paolo A.
    Lopez-Martin, Jose
    Brossart, Peter
    Rohrberg, Kristoffer
    Mellado, Begona
    Fischer, Bruce S.
    Meadows-Shropshire, Stephanie
    Saci, Abdel
    Callahan, Margaret K.
    Rosenberg, Jonathan
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (19) : 1608 - 1616
  • [27] Retrospective analysis of safety and efficacy of ipilimumab in elderly patients with advanced melanoma.
    Shaw, Andrew Cota
    VanAnh Trinh
    Bassett, Roland L.
    Glitza, Isabella Claudia
    Diab, Adi
    Amaria, Rodabe Navroze
    Tawbi, Hussein Abdul-Hassan
    Davies, Michael A.
    Hwu, Wen-Jen
    Hwu, Patrick
    Patel, Sapna Pradyuman
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [28] Efficacy of ipilimumab 10 mg/kg in advanced melanoma patients (pts) with good and poor prognostic factors
    Wolchok, J. D.
    de Pril, V.
    Linette, G.
    Waterfield, W.
    Gajewski, T.
    Chiarion-Sileni, V.
    Ibrahim, R.
    Chin, K.
    Hoos, A.
    Hamid, O.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [29] Dramatic Responses to High-Dose Ipilimumab Plus Temozolomide After Progression on Standard- or Low-Dose Ipilimumab in Advanced Melanoma
    Williamson, Julie
    Fadlullah, Muhammad Zaki Hidayatullah
    Kovacsovics-Bankowski, Magdalena
    Gibson, Berit
    Swami, Umang
    Erickson-Wayman, Alyssa
    Jamison, Debra
    Sageser, Dan
    Jeter, Joanne
    Bowles, Tawnya L.
    Cannon, Donald M.
    Haaland, Ben
    Schroeder, Joyce D.
    Nix, David A.
    Atkinson, Aaron
    Hyngstrom, John
    Mcpherson, Jordan
    Tan, Aik-Choon
    Hu-Lieskovan, Siwen
    CURRENT ONCOLOGY, 2025, 32 (03)
  • [30] Overall survival (OS) and safety results from a phase 3 trial of ipilimumab (IPI) at 3 mg/kg vs 10 mg/kg in patients with metastatic melanoma (MEL)
    Ascierto, P. A.
    Del Vecchio, M.
    Robert, C.
    Mackiewicz, A.
    Chiarion-Sileni, V.
    Arance Fernandez, A. M.
    Schmidt, H.
    Lebbe, C.
    Bastholt, L.
    Hamid, O.
    Rutkowski, P.
    McNeil, C.
    Garbe, C.
    Loquai, C.
    Dreno, B.
    Thomas, L.
    Grob, J. J.
    Hennicken, D.
    Qureshi, A.
    Maio, M.
    ANNALS OF ONCOLOGY, 2016, 27
12345